IP Library Granted Patent US 10,220,116
Granted Patent B2
US 10,220,116 · App. 15/678,176 · Granted Mar 5, 2019

Liquefaction of bone matrix

Inventors: Michael Francis (Norfolk, VA); Roy Ogle (Norfolk, VA)
Assignee: Lifenet Health
A61L27/3687A61K35/28A61K35/32A61K38/1875A61L27/28A61L27/3608A61L27/3821A61L27/3847A61L27/54C12N5/0068C12N5/0654C12N5/0662A61F2210/00A61L2300/414A61L2400/12A61L2430/02C12N2501/155C12N2506/1346C12N2533/30C12N2533/90
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 10,220,116
App. No.
15/678,176
Granted
Mar 5, 2019
Kind
B2
Abstract

The invention relates to methods of preparing a bone matrix solution, a bone matrix implant, and variants thereof. The invention also relates to methods of cell culture using the same. The invention further relates to bone matrix scaffolds comprising one or more bone matrix nanofibers, methods of preparing, and methods of use thereof. The invention also relates to methods of culturing cells and promoting differentiation of stem cells using the same.

Claims (11)

1. A synthetic surface partly or wholly coated with a bone matrix, said matrix comprising a solution of bone in an anhydrous solvent, said solvent comprising (i) hexafluoroisopropanol (HFP) or 2,2,2-trifluoroethanol (TFE) and (ii) trifluoroacetic acid (TFA), said matrix being in the form of a colloidal gel.

2. An implant comprising the synthetic surface of claim 1 .

3. The synthetic surface of claim 1 , wherein the bone comprises demineralized bone matrix.

4. The synthetic surface of claim 1 , wherein the bone comprises collagen Type I, wherein more than 60% of the collagen Type I is in its native structure.

5. A method of making a synthetic surface, comprising the steps of:

a) preparing a bone matrix solution by dissolving bone in an amount of an anhydrous solvent comprising (i) hexafluoroisopropanol (HFP) or 2, 2, 2-trifluoroethanol (TFE) and (ii) trifluoroacetic acid (TFA) sufficient to form the bone matrix solution at a temperature lower than about 25° C.;

b) exposing the bone matrix solution to conditions sufficient to evaporate a portion of the solvent to form a colloidal gel;

c) coating a synthetic surface with the colloidal gel; and

d) exposing the coated surface to conditions sufficient to further evaporate an amount of solvent.

6. The method of claim 5 , wherein the dissolved bone comprises demineralized bone matrix.

7. The method of claim 5 , wherein the dissolved bone comprises collagen Type I, wherein more than 60% of the collagen Type I is in its native structure.

Assignments (3)
SECURITY INTEREST Recorded Apr 2, 2021
From: LIFENET HEALTH; SKIN AND WOUND ALLOGRAFT INSTITUTE, LLC
To: TRUIST BANK
Reel/Frame 055815/0623 →
SECURITY INTEREST Recorded Jun 10, 2019
From: LIFENET HEALTH; SKIN AND WOUND ALLOGRAFT INSTITUTE, LLC
To: SUNTRUST BANK
Reel/Frame 049424/0312 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Nov 16, 2017
From: FRANCIS, MICHAEL; OGLE, ROY
To: LIFENET HEALTH
Reel/Frame 044153/0587 →
Continuity (4)
Division 15138384 · Apr 26, 2016
Division 14377272
Provisional Application 61596027 · Feb 7, 2012
Related Publication 20170368227A1 · Dec 28, 2017